Read More

Axos Fights Back Against Short Seller’s ‘Evergreening’ Allegations

Axos Financial says Hindenburg Research's short report is misleading and false. Its latest earnings call provided credit updates and there have been no changes since then, company says. ment and the company's favorable credit metrics are not manipulated. AX shares are up 0.32% at $50.41.

AX

Read More

Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move Forward

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (ranitidine) to proceed. This ruling contradicts a Federal Court's 2022 decision dismissing similar cases, potentially increasing GSK's liability.

GSK